Literature DB >> 24777964

Harnessing the potential of radiation-induced immune modulation for cancer therapy.

Mansoor M Ahmed1, James W Hodge, Chandan Guha, Eric J Bernhard, Bhadrasain Vikram, C Norman Coleman.   

Abstract

The conventional use of radiotherapy is for local tumor control. Radiotherapy of the primary tumor can prevent the development of distant metastases, but this modality is generally not effective for treating preexisting systemic disease. However, radiation-induced tumor destruction may be considered a novel strategy for in situ cancer vaccination, in which tumor antigens released from dying tumor cells may be presented in an immunostimulatory context. Moreover, radiation has been demonstrated to induce immunogenic modulation in various tumor types by altering the biology of surviving cells to render them more susceptible to T cell-mediated killing. Finally, radiotherapy typically has a favorable toxicity profile and is associated with the absence of systemic immunosuppression. Together, these properties suggest that radiotherapy may serve as an important component of combinatorial immunotherapies aimed at augmenting systemic antitumor immunity. Here, we provide an overview of the radiation-induced modulations of the immune system that may be harnessed for cancer therapy. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24777964     DOI: 10.1158/2326-6066.CIR-13-0141

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  26 in total

1.  Enhancing the efficacy of radiation therapy: premises, promises, and practicality.

Authors:  C Norman Coleman; Theodore S Lawrence; David G Kirsch
Journal:  J Clin Oncol       Date:  2014-08-11       Impact factor: 44.544

Review 2.  Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials.

Authors:  C Norman Coleman; Geoff S Higgins; J Martin Brown; Michael Baumann; David G Kirsch; Henning Willers; Pataje G S Prasanna; Mark W Dewhirst; Eric J Bernhard; Mansoor M Ahmed
Journal:  Clin Cancer Res       Date:  2016-05-06       Impact factor: 12.531

Review 3.  Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.

Authors:  Yamei Chen; Ying Jin; Xiao Hu; Ming Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-08       Impact factor: 4.553

4.  The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.

Authors:  Paul W Sperduto; Wen Jiang; Paul D Brown; Steve Braunstein; Penny Sneed; Daniel A Wattson; Helen A Shih; Ananta Bangdiwala; Ryan Shanley; Natalie A Lockney; Kathryn Beal; Emil Lou; Thomas Amatruda; William A Sperduto; John P Kirkpatrick; Norman Yeh; Laurie E Gaspar; Jason K Molitoris; Laura Masucci; David Roberge; James Yu; Veronica Chiang; Minesh Mehta
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-29       Impact factor: 7.038

Review 5.  Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities.

Authors:  Charlie Garnett-Benson; James W Hodge; Sofia R Gameiro
Journal:  Semin Radiat Oncol       Date:  2015-01       Impact factor: 5.934

6.  Radiation-Drug Combinations to Improve Clinical Outcomes and Reduce Normal Tissue Toxicities: Current Challenges and New Approaches: Report of the Symposium Held at the 63rd Annual Meeting of the Radiation Research Society, 15-18 October 2017; Cancun, Mexico.

Authors:  Kelly C Falls; Ricky A Sharma; Yaacov R Lawrence; Richard A Amos; Sunil J Advani; Mansoor M Ahmed; Bhadrasain Vikram; C Norman Coleman; Pataje G Prasanna
Journal:  Radiat Res       Date:  2018-10       Impact factor: 2.841

7.  Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia in glioblastoma patients: phase II randomized study of protons vs photons.

Authors:  Radhe Mohan; Amy Y Liu; Paul D Brown; Anita Mahajan; Jeffrey Dinh; Caroline Chung; Sarah McAvoy; Mary Frances McAleer; Steven H Lin; Jing Li; Amol J Ghia; Cong Zhu; Erik P Sulman; John F de Groot; Amy B Heimberger; Susan L McGovern; Clemens Grassberger; Helen Shih; Susannah Ellsworth; David R Grosshans
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

Review 8.  Opportunities in immunotherapy of ovarian cancer.

Authors:  G Coukos; J Tanyi; L E Kandalaft
Journal:  Ann Oncol       Date:  2016-04       Impact factor: 32.976

9.  All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages.

Authors:  Enyu Rao; Yuzhu Hou; Xiaona Huang; Liangliang Wang; Jiaai Wang; Wenxin Zheng; Hengjin Yang; Xinshuang Yu; Kaiting Yang; Jason Bugno; Xingchen Ding; Everett Vokes; Yang-Xin Fu; Ralph R Weichselbaum; Hua L Liang
Journal:  Sci Immunol       Date:  2021-06-15

10.  VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy.

Authors:  J Louise Lines; Lorenzo F Sempere; Thomas Broughton; Li Wang; Randolph Noelle
Journal:  Cancer Immunol Res       Date:  2014-06       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.